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Major depressive disorder (MDD) is the most common psychiatric disorder and the second
overall cause of disability. Even though a significant amount of the variance in the MDD
phenotype is explained by inheritance, specific genetic variants conferring susceptibility to
MDD explain only a minimal proportion of MDD causality. Moreover, genome-wide association
studies have only identified two small-sized effect loci that reach genome-wide significance. In
this study, a group of Mexican-American patients with MDD and controls recruited for a
pharmacogenetic study were genotyped for nonsynonymous single-nucleotide polymorph-
isms (nsSNPs) and used to explore the interactions of multiple functional genetic variants with
risk-classification tree analysis. The risk-classification tree analysis model and linkage
disequilibrium blocks were used to replicate exploratory findings in the database of genotypes
and phenotypes (dbGaP) for major depression, and pathway analysis was performed to
explore potential biological mechanisms using the branching events. In exploratory analyses,
we found that risk-classification tree analysis, using 15 nsSNPs that had a nominal association
with MDD diagnosis, identified multiple increased-MDD genotype clusters and significant
additive interactions in combinations of genotype variants that were significantly associated
with MDD. The results in the dbGaP for major depression disclosed a multidimensional
dependent phenotype constituted of MDD plus significant modifiers (smoking, marriage
status, age, alcohol abuse/dependence and gender), which then was used for the association
tree analysis. The reconstructed tree analysis for the dbGaP data showed robust reliability and
replicated most of the genes involved in the branching process found in our exploratory
analyses. Pathway analysis using all six major events of branching (PSMD9, HSD3B1, BDNF,
GHRHR, PDE6C and PDLIM5) was significant for positive regulation of cellular and biological
processes that are relevant to growth and organ development. Our findings not only provide
important insights into the biological pathways underlying innate susceptibility to MDD but
also offer a predictive framework based on interactions of multiple functional genetic variants
and environmental factors. These findings identify novel targets for therapeutics and for
translation into preventive, clinical and personalized health care.
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Introduction
Most genetic diseases, Mendelian or not, are now
known to be complex;
1 the broad strategy used to
identify Mendelian disease genes, which requires that
each susceptibility factor have a large independent
effect on disease risk, has not been successful for
common and complex disorders.
2 In spite of the
recent application of genome-wide association stu-
dies,
3 which have identified hundreds of genetic
variants associated with chronic illnesses, the search
for and interpretation of these genetic associations
continue to be a daunting task. In many cases, asso-
ciated genetic variants account for a very small com-
ponent of the phenotypic variance (B3%), despite
high estimates of heritability (B0.80).
4 Because of this
disappointingly small power for phenotypic predic-
tion, several authors have suggested that genome-
wide association study is more informative about the
novel biological pathways rather than for the clinical
diagnosis and use in predictive medicine.
5,6
It has been proposed that multifactorial disorders
fit the ‘common disease–common alleles model’,
2 Received 2 December 2011; revised 30 January 2012; accepted 30
January 2012; published online 27 March 2012
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www.nature.com/mpin which the cumulative linear impact of multiple
common small-effect genetic variants (gene–gene
interactions) in the context of environmental expo-
sures to increase the individual risk, exceed a bio-
logical threshold and produce an altered phenotype
(genetic–environment interactions).
3 It is also reason-
able to assume that larger risks will emerge from the
nonlinear interaction of rare genetic variant with
major effect. Nonsynonymous single-nucleotide poly-
morphisms (nsSNPs) are a main type of ‘functional’
SNPs, as they result in true amino-acid variation, and
consequently may have a major impact on phenotype.
Major depressive disorder (MDD) is a complex
illness characterized by a triad of symptoms: low or
depressed mood, loss of interest or pleasure in almost
all activities (anhedonia) and low energy/fatigability;
7
MDD represents the second cause of disability.
7,8 In
the United States, suicide, mostly a consequence of
depression, is the eleventh overall cause of death; the
third cause of death in the age group of 15–24 years
and the fourth cause of death in the age group of 25–
44 years.
9 The economic burden of depression to the
US economy is $100 billion annually.
10 MDD herit-
ability is estimated at 0.36–0.7 based on twin
studies,
11 that is, a significant genetic component
underlies MDD susceptibility. Several candidate-gene
approaches disclosed intriguing association of MDD
to genetic variants, whereas genome-wide association
studies only reported two loci that reached genome-
wide significance.
12,13
This study was designed to investigate relation-
ships/gene–gene interactions defined by nsSNPs in
the pathways relevant to central nervous system
function in case-control samples to find recurrent
functional process themes in MDD.
Materials and methods
Subjects
Mexican-American sample. This sample of cases and
controls consists of 321 healthy controls and 278 MDD
aged 19 years or older (Supplementary Table 1). All
participants were Mexican-Americans and had at least
three grandparents born in Mexico. MDD was defined
using the DSM-IV (Diagnostic and Statistical Manual
of Mental Disorders, 4th edn) diagnosis of current,
unipolar major depressive episode as assessed by the
structured clinical interview for DSM-IV and a HAM-
D21 (21-Item Hamilton Depression Rating Scale) score
of X18 with item number 1 (depressed mood) rated
X2. MDD patients were recruited in a pharmaco-
genetic study approved by the Institutional Review
Boards of the University of California Los Angeles,
University of Miami and Australian National University,
and it has been registered in ClinicalTrials.gov
(NCT00265292) as previously described.
14–16 Briefly,
in their primary language, all MDD patients had a
comprehensive psychiatric and medical assessment
based on the diagnostic and ratings instruments that
had been fully validated in English and Spanish.
Exclusion criteria included active medical illnesses
that could be etiologically related to the ongoing
depressive episode, current or active suicidal ideation
with a plan and strong intent, pregnancy, lactation,
current use of medications with significant central
nervous system activity, which interfere with electro-
encephalographic activity (for example, benzodia-
zepines) or any other antidepressant treatment within
the 2 weeks prior to enrollment, illicit drug use and/
or alcohol abuse in the last 3 months or current
enrollment in psychotherapy.
14–16 Control individuals
for our genomic studies were in general good health
but were not screened for medical or psychiatric illness,
they were age- and gender-matched and recruited from
the same Mexican-American community in Los Angeles
by the same bilingual clinical research team.
14–16
Database of genotypes and phenotypes (dbGaP) sample
data. We used genome-wide association study geno-
type information from the major depression dbGaP
17
for replication purposes. Briefly, dbGaP provides
open access to large samples of genetic and pheno-
typic datasets (this particular dataset included 1862
participants affected with major depression and 1857
unaffected controls).
17
Genomic DNA collection and genotyping
At the initial visit, blood samples were collected
under informed consent from the participating in-
dividuals into EDTA (K2EDTA) BD Vacutainer EDTA
tubes (Becton Dickinson, Franklin Lakes, NJ, USA),
and genomic DNA was isolated from those samples
using Gentra Puregene DNA purification kits (Gentra
Systems, Indianapolis, IN, USA). A total of 372
autosomal nsSNPs were selected in 188 genes from
dbSNP (build 121). SNP assays were designed and
typed with the Golden Gate assay as part of a 1536
multiplex reaction (59). DNAs with poor results (50%
GC score <0.65) as well as loci with a low clustering
score (<0.3) were removed. The threshold for retain-
ing individual genotype calls was set to a score of
0.25. Data quality was assessed using duplicate DNAs
across all plates. Genotypes from no matching or
missing duplicates were dropped.
Data analysis
Standard genetic association analysis. The Mexican-
American sample was used as a discovery-exploratory
sample. Quality control and the standard genetic
filters were applied following the STREGA statement
checklist.
18 Testing for Hardy–Weinberg equilibrium,
a more appropriate approach when one allele is very
rare, was performed as implemented in PLINK (http://
pngu.mgh.harvard.edu/~purcell/plink/). Deviation
from Hardy–Weinberg equilibrium was tested
separately for control and depressed groups.
Nonsynonymous SNPs were excluded from the data
analysis if they met the following criteria: SNP assays
were successfully genotyped on <90% of samples,
failed an exact test of Hardy–Weinberg equilibrium in
Prediction of susceptibility to major depression
M-L Wong et al
625
Molecular Psychiatrycontrols (p<0.01) or were monoallelic in the whole
sample. To control and identify the presence of
hidden case-control genetic stratification, a major
cause of discovering spurious associations, we
applied rigorous strategies to discriminate genetic
subdivision as described elsewhere.
14,19
Student’s t-test was conducted to compare age and
baseline HAM-D21 score means, and Pearson’s w
2 test
was performed to compare gender ratios between the
subgroups using SAS version 9.1 (SAS Institute, Cary,
NC, USA). Genotypic association with disease status
was investigated based on two genetic models:
dominant (homozygous for major allele versus the
remaining genotypes) and recessive (homozygous for
minor allele versus the remaining genotypes). Either
the Pearson’s w
2 test or the Fisher’s exact test,
whenever any cell count was <5, was applied using
PLINK. Odds ratio (OR) and its 95% confidence
interval were calculated using either the Woolf’s
method or the exact logistic regression model as
implemented in SAS to appropriately handle fre-
quency tables that contain cells with zero counts.
20
Gene–gene interaction analyses. Additive interaction
between two genetic variants was measured based on
three measures: relative excess risk due to interaction
(RERI=OR11 OR10 OR01þ1), attributable proportion
due to interaction (AP=RERI/OR11) and Rothman’s
synergy index (S=(OR11 1)/(OR10þOR01 2)), where
subscript 0 denotes the absence of the risk genotype at
the SNP and OR denotes the odds ratio. No interaction
corresponds to RERI=0, AP=0 and S=1, whereas
RERI>0, AP>0 and S>1 indicate an increase in the
effect due to the additive interaction.
21,22
Linkage disequilibrium analysis and SNP tagging for
dbGaP. HapMap databases (genotypes and phased
haplotypes, phase III, release 2) were used to identify
linkage disequilibrium blocks harboring SNPs
significantly associated to depression risk in the
Mexican-American sample. We then selected the
dbGaP SNPs in the identified linkage disequilibrium
blocks and performed the same comprehensive and
extensive array of genetic association tests applied to
the Mexican-American sample.
Advance recursive partition (tree-based) approach
(ARPA). We applied tree-based approaches because
they are currently the most used in predictive analyses
as they account for non-linear effects, fast solution for
hidden complex substructure (gene–gene and gene–
demography interactions) and release of truly non-
biased, statistically significant analysis of highly
dimensional, seemingly unrelated data. Furthermore,
results supplied by tree-based analytics are easier to
be visually and logically interpreted. Thus, we
employed ARPA to test high-order gene–gene and
gene–covariates (demographic data) interactions as it
is implemented in HelixTree. Briefly, the basic process
in recursive partitioning analysis is to divide a data set
into parts where the individuals in each segment share
common features. The dependent variable was the
response MDD affection status, and genetic as well as
demographic variables were used as predictors. Trees
were interactively explored with the following restrictive
criteria: (i) at least five elements per child to avoid
small, possibly outlier groups, a common artifact con-
sequence of recursive partitioning; (ii) an exact O(n
2)
algorithm for segmenting; (iii) a maximum cardinality
of five for the multi-way split; (iv) a resampling
approach with 5000 iterations to define the smallest
bound for the P-value; and (v) split-stopping criteria
defined as P-value p0.05 (corrected by Bonferroni).
Prediction of functional effect of human nsSNPs. We
used the freely available Polymorphism phenotyping
(PolyPhen-2) tool for predicting whether a specific
nsSNP may be damaging
23 (http://genetics.bwh.
harvard.edu/pph2/).
Pathway and network analyses. In order to evaluate
potential common ontogenetic as well as cellular
process functionality of those genes disclosed by the
ARPA analysis, we used Metacore 6.8 software build
29806 (GeneGo, St Joseph, MI, USA) tools to build
networks using the list of six genes that had signi-
ficant events of branching process.
Results
Discovery and exploratory phase with the Mexican-
American data
After quality control filters were applied and Hardy–
Weinberg equilibrium tested, a total of 252 nsSNPs in
155 genes were available for analytical procedures
(Supplementary Table 2). It is relevant to mention that
SNP frequency may vary widely among different
ethnic populations. We studied Mexican-American
individuals (Supplementary Table 3 shows the influ-
ence of ethnicity in significant nsSNPs); conse-
quently, those frequencies may influence the risk-
assessment tree structure. For this reason, we repli-
cated this work in the dbGap sample.
In all, 15 nsSNPs showed significant genotypic
association with the diagnosis of MDD (Table 1); 11
and 6 of those nsSNPs fit better a dominant and a
recessive model, respectively.
ARPA analyses performed to assess MDD risk in
clusters of variants showed that eight nsSNPs had
high-order interactions in the control of tree growth
(Figure 1). Our tree model provided 40% sensitivity
to the diagnosis of MDD, 83% specificity for predic-
tion of controls and 63% accuracy for the corrected
prediction of MDD or control subjects. Significant
additive interactions between two genetic variants
were found for nine genotype combinations (Table 2).
Replication phase with the dbGaP sample
A preliminary univariate phenotype analysis reported
significant associations to markers harbored at
markers tagging HSD3B1, PDLIM5, INMT, ADRA1A
and PSMD9 (Table 3). By controlling effects of
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age, sex and comorbidities (substance abuse/depen-
dence (nicotine and alcohol), among other variables),
all of them available at dbGaP (Supplementary
Table 4), we created a multidimensional MDD plus
modifiers phenotype that explained a significant
phenotype variance associated to the MDD pheno-
type. Using the multidimensional MDD plus modi-
fiers phenotype, ARPA reconstructed a tree extra-
ordinarily resembling the tree generated during the
exploratory phase with the Mexican-American MDD
sample. This dbGaP-based tree replicated most of the
genes involved in the branching process; that is, the
first five very significant events of branching are
provided by: PDE6C, PSMD9, HSD3B1, BDNF,
GHRHR and PDLIM5 (Figure 2).
Pathway analyses
We used all six genes generated by significant events
of branching provided by our dbGaP analyses, that
is, PDE6C, PSMD9, HSD3B1, BDNF, GHRHR and
PDLIM5, to build networks and perform the pathway
analyses (Figure 3). These genes form a network with
156 interactions. Significant biological processes
Table 1 nsSNPs showing significant genotypic association with depression
Model Gene (location) SNP Genotype Case Control OR (95% CI) P
a PolyPhen-2
score,
prediction
Dominant HSD3B1 (1p13.1) rs6205 F286L CC/CT 49 30 2.10 (1.29, 3.41) 0.002 Score 0.000
TT 226 290 Reference Benign
PSMB4 (1q21) rs4603 I234T CC/CT 125 173 0.70 (0.51, 0.97) 0.03 Score 0.971
TT 151 146 Reference Probably
damaging
ALDH9A1 (1q23.1) rs1065756 S221T CC/CG 34 24 1.73 (1.00, 3.00) 0.05 Score 0.000
GG 240 293 Reference Benign
PDLIM5 (4q22) rs7690296 T272A GG/GA 206 202 1.65 (1.16, 2.35) 0.005 Score 0.000
AA 71 115 Reference Benign
NFKB1 (4q24) rs4648072 M507V GG/GA 1 8 0.14 (0.02, 1.17) 0.04 Score 0.0069
AA 276 312 Reference Benign
INMT (7p15) rs4723010 D28N AA/AG 126 181 0.64 (0.46, 0.89) 0.007 Score 0.002
GG 149 137 Reference Benign
GHRHR (7p14) rs4988496 A57T AA/AG 14 33 0.47 (0.24, 0.89) 0.02 Score 0.000
GG 262 288 Reference Benign
ADRA1A (8p21-p11) rs2229125 I200S GG/GT 38 27 1.73 (1.02, 2.91) 0.04 Score 1.000
TT 239 293 Reference Probably
damaging
BDNF (11p13) rs6265 V66M AA/AG 57 98 0.58 (0.40, 0.85) 0.005 Score 0.604
GG 220 221 Reference Possibly
damaging
ACE (17q23.3) rs4318 S49G GG/GA 1 10 0.11 (0.01, 0.89) 0.01 Score 0.013
AA 274 310 Reference Benign
USP36 (17q25.3) rs3744793 V271I AA/AG 195 197 1.55 (1.10, 2.19) 0.01 Score 0.009
GG 78 122 Reference Benign
COMT (22q11.21) rs6267 A72S TT/TG 13 32 0.48 (0.25, 0.94) 0.03 Score 0.215
GG 235 279 Reference Benign
Recessive MYOC (1q23-q24) rs2234926 R76K AA 7 1 8.36 (1.02, 68.41) 0.03 Score 0.988
AG/GG 267 319 Reference Probably
damaging
INMT (7p15) rs2302339 M205V GG 6 22 0.32 (0.13, 0.81) 0.01 Score 1.000
GA/AA 251 296 Reference Probably
damaging
GHRHR (7p14) rs2228078 M422T CC 22 11 2.40 (1.14, 5.05) 0.02 Score 0.002
CT/TT 254 305 Reference Benign
NAT2 (8p22) rs1208 R268K GG 29 58 0.53 (0.33, 0.86) 0.01 Score 0.062
GA/AA 243 260 Reference Benign
PDE6C (10q24) rs701865 S270T AA 58 41 1.84 (1.19, 2.85) 0.006 Score 0.000
AT/TT 212 276 Reference Benign
PSMD9 (12q24) rs1043307 E197G GG 65 47 1.76 (1.16, 2.67) 0.007 Score 0.174
GA/AA 211 269 Reference Benign
Abbreviations: CI, confidence interval; OR, odds ratio; nsSNPs, nonsynonymous single-nucleotide polymorphisms; SNP,
single-nucleotide polymorphism.
aBased on Fisher’s exact test if cell count<5.
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cellular and biological processes, nerve growth-factor
receptor signaling pathway, and regulation of cell
death (Supplementary Table 5).
Prediction of functional effect of human nsSNPs
Most variations are predicted to be benign (Table 1).
Variations rs4603 (PSMB4), rs2229125 (ADRA1A),
rs2234926 (MYOC) and rs2302339 (INMT) are pre-
dicted to be probably damaging and variation rs6265
(BDNF) is predicted to be possibly damaging.
Discussion
We showed that genetic analyses as well as classifi-
catory multidimensional tree techniques applied to
nsSNPs associated to MDD diagnosis provided a
reliable branching-tree framework that predicted,
with reasonable sensibility and specificity, the clus-
tering of MDD patients.
The allelic variation rs6265 in the BDNF gene has
been replicated in at least three independent studies
in MDD;
24 this variation is predicted to be possibly
damaging and it has been also implicated in a number
of neuropsychiatric conditions (OMIM 113505). Re-
cently, allelic variations in the PDLIM5 gene have
been implicated in recurrent MDD,
25 bipolar
26 and
schizophrenia.
27 We have reported data supporting
the role of cGMP phosphodiesterases (PDE) genes
28
and the role of immune-related genes relevant to
T-cell function (TBX21 and PSMB4) in MDD.
29
In our discovery/exploratory analyses, the ubiquitin-
proteasome pathway provided a recurrent theme in the
tree structure (Figure 1). Three nsSNPs with high-order
interactions in the control of the tree growth in the
PSMB4, PSMD9 and USP36 genes belong to this
pathway, however, only PSMD9 remained in the
replication tree (Figure 2). PSMD9 is a subunit of the
26S proteasome, which consists of a 20S proteolytic
core capped at both ends by the 19S regulatory
complex that recognizes the polyubiquitin-tagged
substrates. Studies have linked the 26S proteasome
with transcriptional activities through proteolysis of
steroid-hormone receptors to limit their transcriptional
output and recycling of transcriptional complexes
on chromatin to facilitate multiple rounds of trans-
criptional initiation.
30 The ubiquitin-proteasome
pathway is the major system of selective degradation
Figure 1 Tree analyses performed to assess MDD risk in cluster of variants. Eight nsSNPs had high-order interactions in the
control of tree growth; they are located in the following genes: HSD3B1, PDLIM5, PSMD9, BDNF, USP36, PDE6C, PSMB4
and MYOC genes. Light-pink nodes=low MDD risk; light-green nodes=moderate MDD risk; light-blue nodes=high
MDD risk; and purple node=reference MDD risk. Sensitivity=40%, specificity=83% and accuracy=63% (sensitivity refers
to the proportion of cases who are correctly predicted as case; specificity refers to the proportion of controls who are
correctly predicted as control; and accuracy refers to the proportion of cases and controls who are correctly predicted as case
or control).
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Molecular PsychiatryTable 2 nsSNPs showing synergic effects on the risk of depression
Genotype Case Control OR (95% CI) P Measures of additive
interaction
SNP1 (gene 1) SNP2 (gene 2) RERI AP S
rs6205 (HSD3B1) rs1043307 (PSMD9)
TT GA/AA 177 243 Reference
GG 49 44 1.53 (0.97, 2.40) 0.06
CC/CT GA/AA 33 26 1.74 (1.01, 3.02) 0.05
GG 16 3 7.32 (2.10, 15.04) 0.0003 5.05 0.69 4.97
rs7690296 (PDLIM5) rs6265 (BDNF)
AA AA/AG 11 32 Reference
GG 60 83 2.10 (0.98, 4.50) 0.05
GG/GA AA/AG 46 66 2.03 (0.93, 4.43) 0.07
GG 158 135 3.40 (1.65, 6.99) 0.0005 0.27 0.08 1.13
rs7690296 (PDLIM5)
a rs6265 (BDNF)
a
AA AA/AG 10 27 Reference
GG 44 77 1.54 (0.68, 3.48) 0.29
GG/GA AA/AG 37 62 1.61 (0.70, 3.70) 0.26
GG 135 121 3.01 (1.40, 6.47) 0.003 0.86 0.28 1.74
rs7690296 (PDLIM5) rs2234926 (MYOC)
AA GG 55 90 Reference
AA/AG 16 25 1.05 (0.51, 2.13) 0.90
GG/GA GG 164 169 1.59 (1.07, 2.37) 0.02
AA/AG 40 32 2.05 (1.15, 3.55) 0.01 0.41 0.20 1.65
rs7690296 (PDLIM5)
a rs2234926 (MYOC)
a
AA GG 41 82 Reference
AA/AG 13 22 1.18 (0.54, 2.58) 0.68
GG/GA GG 137 155 1.77 (1.14, 2.74) 0.01
AA/AG 35 28 2.50 (1.34, 4.56) 0.004 0.55 0.22 1.58
rs6265 (BDNF) rs2234926 (MYOC)
AA/AG GG 45 71 Reference
AA/AG 12 27 0.70 (0.32, 1.52) 0.37
GG GG 174 188 1.46 (0.95, 2.24) 0.08
AA/AG 44 30 2.31 (1.28, 4.05) 0.005 1.15 0.50 8.14
rs6265 (BDNF)
b rs2234926 (MYOC)
b
AA/AG GG 28 45 Reference
AA/AG 9 17 0.85 (0.33, 2.17) 0.73
GG GG 109 110 1.59 (0.93, 2.74) 0.09
AA/AG 26 11 3.80 (1.63, 7.80) 0.002 2.36 0.62 6.31
rs3744793 (USP36) rs4603 (PSMB4)
GG CC/CT 38 67 Reference
TT 41 53 1.36 (0.77, 2.41) 0.29
AA/AG CC/CT 87 105 1.46 (0.90, 2.38) 0.13
TT 109 91 2.11 (1.30, 3.41) 0.002 0.29 0.14 1.35
rs3744793 (USP36)
c rs4603 (PSMB4)
c
GG CC/CT 5 19 Reference
TT 3 20 0.57 (0.12, 2.72) 0.48
AA/AG CC/CT 6 28 0.81 (0.22, 3.05) 0.76
TT 23 24 3.64 (1.17, 11.41) 0.02 3.26 0.89  4.29
Abbreviations: AP, attributable proportion due to interaction; CI, confidence interval; nsSNPs, nonsynonymous single-
nucleotide polymorphisms; OR, odds ratio; RERI, relative excess risk due to interaction; S: synergy index; SNP, single-
nucleotide polymorphism.
ars6205=TT.
brs6205=TT and rs7690296=GG/GA.
crs6205=TT, rs7690296=AA and rs1043307=GA/AA.
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Chromosome SNP and tagged gene Model Case Control Chi-square (w
2) df P
1 rs6428830 (HSD3B1) Allelic 1003/2579 1109/2503 6.332 1 0.012
Dominant 866/925 941/865 5.062 1 0.024
Genotypic 137/729/925 168/773/865 6.388 2 0.041
rs7553527 (HSD3B1) Allelic 1577/1947 1519/2061 3.888 1 0.049
4 rs12649976 (PDLIM5) Recessive 310/1476 265/1539 4.748 1 0.029
rs13135257 (PDLIM5) Recessive 307/1469 263/1530 4.556 1 0.033
rs17021917 (PDLIM5) Dominant 44/1745 26/1781 4.906 1 0.027
Allelic 44/3534 26/3588 4.858 1 0.028
7 rs4988498 (INMT) Recessive 3/1750 12/1756 5.346 1 0.021
8 rs505138 (ADRA1A) Genotypic 15/285/1483 7/358/1432 12.03 2 0.002
Dominant 300/1483 365/1432 7.191 1 0.007
Allelic 315/3251 372/3222 4.75 1 0.029
12 rs1168658 (PSMD9) Trend 997/2565 934/2666 3.894 1 0.048
rs7313252 (PSMD9) Allelic 1720/1774 1638/1892 5.616 1 0.018
Dominant 1300/447 1256/509 4.686 1 0.030
Abbreviation: SNP, single-nucleotide polymorphism.
Figure 2 ARPA using dbGaP data reconstructed a tree resembling the tree generated during the exploratory phase with the
Mexican-American MDD sample in Figure 1. Most of the genes involved in the branching process, that is, PDE6C, PSMD9,
HSD3B1, BDNF and PDLIM5, were replicated. This tree has one gene (GHRHR) not present in the exploratory tree.
Reconstruction of the tree highlighted that some covariates used by the multidimensional phenotype, that is, nicotine and
alcohol use, provided a significant weight to the process of discriminating MDD-affected individuals from unaffected during
the branching. For easier understanding, Figure 1 tree is reproduced in the right upper corner inset and genes in the two trees
are color-coordinated.
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Molecular Psychiatryof short-lived regulatory proteins in eukaryotic cells,
but it also has an important roles in cell-cycle
regulation, signal transduction, differentiation, antigen
processing, immune function and degradation of
tumor suppressors.
30
In Figure 1, the variation rs6205 in the HSD3B1
gene, which defined the root (topmost) node in our
risk-assessment tree, is located in a putative mem-
brane-binding domain.
31 The genotype TT in rs6205
(HSD3B1) is prevalent in the population, whereas the
CC/CT variants of rs6205 (HSD3B1) conferred a small
increment in MDD risk, which in combination with
the PSMD9 genotype GG (in rs1043306) defined the
highest MDD percentage-increased risk (84%, node
12). This cluster of genotypes represents an increase
of six-fold in MDD risk compared with our reference
node 6 (47%). Clusters of genotypes can confer low
risk (nodes 1, 2, 5 and 9) or increased risk for MDD (3
and 4 are moderate MDD risk and nodes 7, 8, 10, 11
and 12 are high MDD risk, ORX1.9). Three subtrees
emerged in our main tree structure: two outer (right
and left) and one middle subtrees. Outer subtrees
contained several representations of the ubiquitin-
proteasome pathway components (PSMD9, USP36
and PSMB4 in the left subtree, and PSMD9 and
PSMB4 in the right subtree) and the middle subtree
contained the BDNF rs6265 variation. Of note, is the
presence of genes relevant to visual function (MYOC
and PDE6C) in the subtrees that contain high-risk
MDD nodes (Figure 1 middle and right subtrees) and
their absence in the left subtree, which carries low-
and moderate-risk MDD nodes. Variation rs2234926
(MYOC) is predicted to be possibly damaging; varia-
tions in the MYOC gene have been associated with
glaucoma. PDE6C is a phosphodiesterase enzyme
abundantly found in the eye. In our replication tree,
only PDE6C remained (Figure 2).
Our replication study used an MDD-independent
sample (dbGaP data) and tagged markers in linkage
disequilibrium to the nsSNPs (Figure 2). It showed an
extraordinary reliability for most genes involved in
the branching-tree process depicted by the explora-
tory analysis. It also revealed that comorbidities, such
as, nicotine, alcohol abuse, among others, included as
covariate information might provide a better predic-
tion of the status outcome. Additionally, network
analyses showed that genes involved in those major
branching events are related to positive regulation of
Figure 3 Network analyses showed that all the genes involved in the major branching events in Figure 2 are related to
positive regulation of cellular, biological processes and relevant to growth and organ development (the nerve growth-factor
signaling pathway and retinal cone-cell development, also see Supplementary Table 5). All the symbols are explained in the
MetaCore legend (Supplementary Material, Supplementary Figure 1).
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and organ development.
Our study provides an initial functional pathway
map which helps elucidate the pathophysiology of
mild to moderate forms of MDD. This approach has
the potential to enhance our understanding of the
contributions of gene–gene variations to MDD risk.
We have not conducted an extensive nsSNP survey;
therefore, other pathways may also contribute to MDD
risk. Future work should further assess the interac-
tions of nsSNPs and environmental factors in major
depression in diverse population groups.
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